

Number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of the exercise of warrants under the company's incentive programs.

Through the exercise of warrants under the company's incentive program, LTIP 2015/2021, the number of outstanding shares and votes has increased by 175,000 to 19,067,504. The share capital has increased by SEK 175,000 from SEK 18,892,504 to SEK 19,067,504.

With reference to the press release on August 21, the shares now registered are part of the total number of warrants that have been exercised to subscribe for shares. The LTIP 2015/2021 warrant program has now been terminated and the company announces that all warrant holders have exercised their opportunity to subscribe for shares.

For further information, please contact:

Per Andersson, CEO, Xspray Pharma AB
Phone: +46 (0) 706 88 23 48
E-mail: per.andersson@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharma company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company's innovative technology allows Xspray Pharma to gain entry as the first competitor to today's original drugs before the secondary patents expire. Xspray's goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 55 in December 2020. The company's leading product candidates, HyNap-Dasa, HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tassigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed in two versions, a generic and an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tassigna and has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com

This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2021-01-29 15:45 CET.

Attachments

[Number of shares and votes in Xspray Pharma](#)